A therosclerosis is a chronic inflammatory disease characterized by the accumulation of lipids and fibrous elements in large arteries. [1] [2] [3] This complex disease involves interactions of modified lipoproteins, monocyte-derived macrophages or foam cells, T lymphocytes, endothelial cells (ECs), vascular smooth muscle cells (VSCMs), and fibroblasts. Monocytes and macrophages lead to the inflammatory pathology of atherosclerosis, whereas changes in athermanous plaque thickness and matrix composition are attributed to VSMCs. VSMCs are responsible for promoting plaque stability in advanced lesions. In this regard, studies from Bennett laboratory have elegantly demonstrated that VSMC apoptosis alone is sufficient to induce multiple features of atherosclerotic plaque vulnerability. 4 Interestingly, in vitro studies have indicated that VSMCs isolated from atheromas in humans and mice have downregulated the activity of the Akt signaling pathway and are more prone to apoptosis. 4, 5 The serine/threonine kinase Akt (also known as protein kinase B) is a multifunctional kinase implicated in the regulation of cellular growth, survival, and metabolism. 6, 7 Akt is at the center of a complex signaling network regulating multiple cellular functions, suggesting a possibility that Akt signaling pathways may be involved in the pathogenesis of atherosclerosis. Mammalian cells express 3 Akt isoforms (Akt1, Akt2, and Akt3) encoded by 3 separate genes. 8 Despite their similarity, gene knockout studies have shown that the 3 Akt isoforms have some nonredundant functions. The relative expression of the 3 isoforms varies between tissues, with Akt1 being the most abundantly expressed. 9 Akt1 regulates multiple functions in the cardiovascular system, playing an important role during angiogenesis, apoptosis, and regulation of cardiac hypertrophy. [10] [11] [12] In vitro studies suggest that Akt1 might play either a proatherogenic or antiatherogenic role, possibly because of compensation by multiple isoforms when a single isoform is deleted. For example, nitric oxide (NO), derived from endothelial NO synthase (eNOS), has physiological properties that can be atheroprotective, including the inhibition of apoptosis, VSMC proliferation, platelet aggregation and adhesion, and leukocyte activation and adhesion. 13, 14 However, PI3K-Akt signaling pathway activation enhances macrophage survival in lesions, and the persistent activation of Akt promotes cellular hypertrophy and hyperplasia, thereby promoting atherogenesis. 11, 15 Most importantly, the absence of global Akt1 in an ApoE-deficient background leads to severe atherosclerosis because of the enhanced expression of proinflammatory genes and EC and macrophage apoptosis. 16 Bone marrow transplantation experiments demonstrated that macrophages from ApoE −/− Akt1 −/− donors did not confer increased atherogenesis, suggesting that the lesion expansion in those mice may be of vascular origin. However, these studies were performed in whole body Akt1-deficient mice, which do not allow for the specific interrogation of Akt1 in VSMCs during the progression of atherosclerosis. Thus, to assess the role of Akt1 in VSMCs during atherogenesis in vivo, we generated 2 novel mouse models in which Akt1 expression can be suppressed in VSMCs before (Apoe 
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CRE mice develop features of plaque vulnerability, such as thinner fibrous caps, reduced collagen deposition, increased necrotic cores, and enhanced VSMC apoptosis. Similarly, inducible genetic silencing of Akt1 in mice with established atherosclerotic plaques results in thinner fibrous caps. Altogether, these findings provide genetic evidence demonstrating the critical role of Akt1 at different stages of atherogenesis and suggest that Akt1 activation in advanced plaques may be beneficial for treating coronary artery disease.
Methods
Materials and Methods are available in the Online Data Supplement. Figure 1B [right], quantification). The expression levels of Akt2, the other major Akt isoform in VSMCs, were similar in both groups of mice ( Figure 1B) . Surprisingly, we found a moderate but significant decrease in p-Akt levels, suggesting that Akt2 could be more activated and help compensate the loss of Akt1 in VSMCs. We did not find differences in proliferating cell nuclear antigen expression between both genotypes ( Figure 1B ). We next examined multiple metabolic parameters in the mice. As seen in Figure 1C -1E, VSMC-specific Akt1 genetic deletion did not influence body weight, total cholesterol, or triglycerides at various time points during the study. Figure 1F [right], quantification). However, we observed a modest, but significant, increase in atherosclerotic plaque size in mice lacking Akt1 in VSMCs after 5 months of feeding a WD ( Figure 1F [right], quantification). Even though the differences in plaque size were small, we found a marked change in the morphology of atherosclerotic plaques isolated from Apoe 
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Generation and Characterization of Apoe
Prolonged Akt1 Inhibition in VSMCs Results in Accelerated Atherosclerosis and Increased Plaque Necrosis
Absence of Akt1 in VSMCs Increases Apoptosis in Atherosclerotic Plaques
The increase in plaque necrosis observed in Apoe
Sm22α CRE mice could reflect a primary increase in VSMC apoptosis. Therefore, we examined cellular apoptosis using terminal deoxynucleotidyl transferase dUTP end labeling staining in cross-sections of the aortic sinus. We found that apoptosis was markedly increased in smooth muscle actinpositive cells ( Figure 3A 
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CRE mice ( Figure 3B [right], quantification). These results suggest that the loss of Akt1 in VSMCs influences not only VSMC survival but also macrophage viability in atherosclerotic lesions. Another interpretation of these results could be that many terminal deoxynucleotidyl transferase dUTP end labeling CD68-positive cells are derived from VSMCs. Indeed, recent reports have shown that ≈50% of CD68-positive cells in mouse and human atherosclerotic plaques are derived from VSMCs. 17, 18 We next analyzed whether the absence of Akt1 in VSMCs influences macrophage and VSMC proliferation in atherosclerotic plaques. To this end, we costained aortic root lesions with Ki-67 (a cellular marker of proliferation) and CD68 or smooth muscle actin. We found that most of Ki-67 positive cells costained with the CD68 marker (Online Figure IA) . Moreover, the number of CD68/Ki-67 and smooth muscle actin/Ki-67 positive cells in atherosclerotic lesions was similar between both groups of mice (Online Figure IB) .
The size and content of the fibrous cap are also regulated by matrix metalloproteases (MMPs), protease enzymes that degrade and remodel the extracellular matrix, and inflammatory cytokines that influence VSMC, EC, and macrophage activation in the artery wall. Sm22α CRE mice fed a WD for 3 and 5 months ( Figure 3C ). In summary, these findings provide the first in vivo evidence that specific genetic ablation of Akt1 in VSMCs results in pronounced changes in atherosclerotic plaque morphology. 
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The migration and proliferation of VSMCs play crucial roles in the development of atherosclerotic lesions. We have previously shown that the absence of Akt1 reduces VSMC migration and proliferation. 19 Figure 4B , experimental outline). As expected by our previous results, mice administered tamoxifen expressed significantly reduced levels of Akt1 ( Figure 4C [right] , quantification). These results demonstrate that our mouse model is adequate to study the contribution of Akt1 in regulating VSMC functions in late stages of atherosclerosis.
Inhibition of Akt1 in VSMCs in Mice With Established Atherosclerotic Plaques Results in a Marked Decrease in Lesion Fibrous Cap Area
We next examined the effects of inhibiting VSMC Akt1 on plaque size and morphology. In contrast to the results obtained in mice lacking Akt1 before atherosclerotic lesions develop, silencing Akt1 during the late stage of atherosclerosis does not influence plaque size ( Figure 4D [right], quantification). However, we found a significant decrease in the lesion fibrous cap area and enhanced apoptosis ( Figure 4E ; Online Figure IIA Figure IIE) . Collectively, these results strongly support an important role for VSMC Akt1 in all stages of atherogenesis.
Discussion
Our study identifies Akt1 as a major factor for controlling VSMC functions during the progression of atherosclerosis. Using 2 novel conditional mouse models, we demonstrate that VSMC Akt1 regulates plaque morphology and its absence promotes VSMC apoptosis and plaque necrosis.
Several groups have studied the contribution of different Akt isoforms during the progression of atherosclerosis. 16, [21] [22] [23] The global absence of Akt1 results in massive atherosclerosis and occlusive arterial disease, a rare phenotype observed in few mouse models of atherosclerosis. 16 In contrast, lack of Akt2 does not influence the progression of atherosclerosis in mice despite the dyslipidemia and glucose intolerance observed in these mice. 22 Surprisingly, we and others recently demonstrated that Akt2 is required for macrophage migration in response to monocyte chemotactic protein-1 and its absence results in an alternatively activated, or M2-type phenotype, when stimulated with proinflammatory cytokines. 22, 24 Akt3 also plays a role during atherogenesis by suppressing macrophage foam cell formation, thereby protecting against the progression of atherosclerosis. 21 These observations demonstrate that Akt2 and Akt3 mostly influence atherogenesis by controlling monocyte/macrophage functions, whereas Akt1 controls the progression of atherosclerosis by regulating vessel wall homeostasis. However, the use of Akt1 global-deficient mice limits the ability to study its specific effect in particular cell types in the artery wall (ie, ECs and VSMCs).
Akt1 regulates important cellular functions in ECs, including eNOS activation and cellular migration and proliferation. Of note, the increased atherosclerosis observed in Akt1-null mice was associated with enhanced apoptosis and reduced eNOS phosphorylation in ECs. Other studies also showed that transgenic expression of an activated form of Akt (myr-Akt) in the endothelium reduces vascular lesion formation in vivo. 25 Moreover, a recent study has also demonstrated that the genetic disruption of the 3 genes encoding for the isoforms of the FoxO transcription factors prevents atherosclerosis. 26 These observations suggest that the enhanced atherosclerosis observed in the Akt1-null mice could be mediated by decreased eNOS activity and increased FoxO transcriptional activation because this family of transcription factors is phosphorylated and inactivated by Akt. Interestingly, loss of the 3 FoxO isoforms in ECs results in a significant downregulation of Akt expression by an unknown mechanism. 26 However, FoxO-deficient mice have a significant increase in eNOS expression and enhanced eNOS-dependent arterial relaxation.
26
Akt1 controls VSMC migration and proliferation, and its activity has been associated with plaque remodeling during atherogenesis. In addition to Akt1, Akt2 also regulates VSMC homeostasis. Indeed, the absence of Akt2 protects against aortic aneurism formation by preventing FoxO1 association with the MMP9 and TIMP1 promoters. 27 Moreover, Akt2 deficiency in Ldlr −/− mice markedly reduces collagen content and increases necrotic cores in atherosclerotic lesions. 28 Thus, both Akt1 and Akt2 seem to regulate VSMC migration and survival during vessel remodeling and atherogenesis.
In this study, we provide definitive evidence that Akt1 in VSMCs regulates the progression of atherosclerosis and lesion morphology. Specifically, we demonstrate that the absence of Akt1 in VSMCs results in profound changes in the morphology of atherosclerotic plaques characterized by larger necrotic core areas and thinner fibrous caps, both features of vulnerable plaques in humans. In agreement with these observations, a recent report has shown that overexpression of Akt1 in VSMCs inhibited VSMC apoptosis during atherogenesis and increased relative fibrous cap area in plaques.
29
This study also identified FoxO3a-Apaf1 as major Akt substrates that mediate Akt1 functions during the progression of atherosclerosis. Apaf1 induces apoptosis in VSMCs, and Akt1 inhibits its activity, thus promoting survival of VSMCs in atherosclerotic lesions. Here, we report that the absence of Akt1 in VSMCs significantly reduces Gsk-3 phosphorylation, which has previously been associated with reduced survival of VSMCs. 5 Gsk-3 regulates apoptosis via phosphorylation and subsequent ubiquitin-mediated degradation of the Bcl-2 family member, myeloid cell leukemia-1, in VSMCs. 5 Interestingly, treatment of hyperglycemic ApoEdeficient mice with valproic acid, an inhibitor of Gsk-3β, had antiatherogenic effects, 30 providing further evidence that Gsk-3β activation may be playing a direct role in the development of advanced atherosclerosis. Moreover, in diabetic pigs fed a WD, the disinhibition of Gsk-3β by hypophosphorylated Akt was associated with an increase in cellular apoptosis and developed advanced atherosclerosis. 31 These observations suggest that the Akt1-Gsk-3 signaling pathway may mediate prosurvival effects in VSMCs. In summary, our data genetically demonstrate the key role of Akt1 in VSMCs during atherogenesis and that Akt1 expression in VSMCs regulates vascular remodeling during the progression of atherosclerosis.
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• Vascular smooth muscle cell (VSMC) apoptosis occurs during the progression of atherosclerosis and in advanced lesions and promotes plaque necrosis, a common feature of high-risk/vulnerable atherosclerotic plaques.
• Akt1 is essential for VSMC proliferation, migration, and protection against oxidative stress-induced apoptosis. However, its specific contribution during the progression of atherosclerosis remains unknown.
What New Information Does This Article Contribute?
• Absence of Akt1 in VSMCs during atherogenesis results in larger atherosclerotic lesions characterized by bigger necrotic core areas, enhanced VSMC apoptosis, and reduced fibrous cap and collagen content.
• Deficiency of Akt1 in the setting of advanced atherosclerosis in mice decreases fibrous caps in the lesions and enhances VSMC apoptosis.
• Prolonged absence of Akt1 in VSMCs results in a marked reduction in glycogen synthase kinase-3 phosphorylation, which has been associated with reduced VSMC survival.
Prominent areas of lesional apoptosis characterize the types of atherosclerotic plaques that cause acute cardiovascular events in humans. However, the specific mechanism that regulates cellular apoptosis and lesion morphology remains to be fully determined. Our study reveals that the expression of Akt1 in VSMCs is critical during the progression and in late stages of atherogenesis. The absence of Akt1 promotes plaque necrosis and enhances VSMC apoptosis. This effect may be mediated by reduced phosphorylation of glycogen synthase kinase-3, which has previously been associated with reduced VSMC survival. 
Genetic evidence supports a major role for Akt1 in VSMCs during atherogenesis
Histology, Immunohistochemistry and Morphometric Analyses.
Mouse hearts were perfused with 10 ml of phosphate-buffered saline (PBS) and were put in 10 ml of 4% paraformaldehyde (PFA) overnight. After incubation in PFA, hearts were washed with PBS and left with PBS for 1 hour. Next, hearts were put in 30% sucrose until the next day. Finally, hearts were embedded in OCT and frozen. Serial sections were cut at 8mm thickness using a cryostat. Every third slide from the serial sections was stained with hematoxylin and eosin (H&E) for quantification of lesion areas. Aortic lesion size of each animal was obtained by averaging the lesion areas in four sections from the same mouse. Collagen content was assessed by Picrosirius red-staining of consecutive slides from serial sections. CD68 staining was used as a macrophage marker using consecutive slides from serial sections (Serotec, MCA1957, 1:200) and was co-stained with monoclonal Anti-Actin α−smooth muscle-Cys antibody (SIGMA, 1:1000) as a SMC marker. Nuclei were counterstained with DAPI for 10 min. The fibrous cap, necrotic core area and macrophage content were measured as a percentage of the total plaque area from the three sections from the same mouse. Apoptotic cells in lesions were detected by TUNEL after proteinase K treatment, using the In situ Cell Death Detection kit, TMR red (Roche). Tri-color immunofluorescence staining was performed on cryosections by using different combinations of antibodies. For instance, in the tri-color labeling of TUNEL, CD68 or SMA and DAPI, heart sections were first performed for TUNEL by following the manufacturer's instructions. Primary antibody for CD68 or SMA was then added and incubated for 1h at RT. After PBS washes secondary antibody was added for 45 min. Then, nuclei were counterstained with DAPI for 10 min. The data were expressed as the number of TUNEL positive cells per CD68 or SMA plaque area. Proliferate cells in lesion were detected by co-stained cryosections using Ki67 (Abcam 66155, 1:100) and CD68 or SMA. Proliferating cells were calculated as the number positive Ki67-labeled nuclei per CD68 or SMA plaque area. ImageJ software (NIHImageJ, USA) was used for all the quantifications.
Lipid measurements.
Mice were fasted for 12-14 hours before blood samples were collected by retro-orbital venous plexus puncture. Then, plasma was separated by centrifugation and stored at -80ºC. Total plasma cholesterol and triglycerides were enzymatically measured (Wako Chemicals, USA) according to the manufacturer's instructions.
Western Blotting.
Tissue from the aortas was lysed in ice-cold buffer containing 50 mM Tris-HCl, pH 7.5, 125 mM NaCl, 1% NP-40, 5.3 mM NaF, 1.5 mM NaP, 1 mM orthovanadate and 1 mg/ml of protease inhibitor cocktail (Roche) and 0.25 mg/ml AEBSF (Roche). Tissue or cell lysates were rotated at 4ºC for 1 hour before the insoluble material was removed by centrifugation at 12000 x g for 10 minutes. After normalizing for equal protein concentration, cell lysates were resuspended in SDS sample buffer before separation by SDS-PAGE. Western blots were performed using the following antibodies: rabbit polyclonal antibodies against phospho-Akt (Ser473) (1:1000), Akt1 (1:1000), Akt2 (1:1000), Akt (1:1000), phospho-GSK-3-beta (Ser9) (1:1000), GSK-3-beta (1:1000), phospho-FoxO1 (Ser256) (1:1000), FoxO1 (1:1000), as well as mouse monoclonal antibodies against PCNA (1:2000) and phospho-Akt (Thr308) (1:1000), which were obtained from Cell Signaling Technology. A mouse monoclonal antibody against HSP-90 (1:1000) was purchased from BD Bioscience. Secondary fluorescently labeled antibodies were from Molecular Probes (Invitrogen). Protein bands were visualized using the Odyssey Infrared Imaging System (LI-COR Biotechnology). Densitometry analysis of the gels was carried out using ImageJ software from the NIH (http://rsbweb.nih.gov/ij/).
RNA isolation and quantitative real-time PCR.
Total RNA from mouse aortas was isolated using the Bullet Blender Homogenizer (Next Advance) in TRIzol reagent (Invitrogen) according to the manufacturer's protocol. 1 µg of total RNA was reverse transcribed using the iScript RT Supermix (Bio-Rad), following the manufacturer's protocol. Quantitative real-time PCR was performed in triplicate using iQ SYBR green Supermix (BioRad) on a Real-Time Detection System (Eppendorf). The mRNA level was normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as a housekeeping gene. Quantitative real-time PCR was performed in triplicate using miScript SYBR Green (QIAGEN) on a Real-Time Detection System (Eppendorf).
The following mice primer sequences were used: GAPDH, 5'-AACTTTGGCATTGTGGAAGG-3′ and 5′-ACACATTGGGGGTAGGAACA-3′; IL-6, 5´-AGTTGCCTTCTTGGGACTGA-3´ and 5´-TCCACGATTTCCCAGAGAAC-3´; IL-1β 5'-CCCAGGAAGACAGGCTTGTGC-3' and 5'-TGCAGCTGGAGAGTGTGGATCC-3'; MCP1, 5´-TCTGGGCCTGCTGTTCAC-3´and 5´-GTGAATGAGTAGCAGCAGGTGAGT-3´; MMP2, 5'-TGTTCTTCGCAGGGAATGAG -3' and 5'-TGCGATGAGCTTAGGGAAAC-3'; and MMP9, 5'-TAGTGAGAGACTCTACACAG-3' and 5'-CCACTTCTTGTCAGTGTCGA.
Statistical Analysis
Data are presented as mean ± the standard error of the mean (SEM) (n is noted in the figure legends), and the statistical significance of the differences was evaluated with the Student´s t test. Significance was accepted at the level of p<0.05. Data analysis was performed using GraphPad Prism 6.0a software (GraphPad, San Diego, CA). 
